Health Affairs, 25, no. 5 (2006): 1204 doi: 10.1377/hlthaff.25.5.1204 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Health Reform Insurance Coverage Pharmaceuticals Research And Technology Health Spending

Coverage

PROLOGUE

Insurance Coverage Of Biopharmaceuticals

It is by now readily apparent to all concerned that new, breakthrough biopharmaceuticals pose a difficult challenge to existing arrangements for financing care because of their high costs, the small patient populations they often serve, and problems in measuring their incremental therapeutic value. How the U.S. health system deals with this challenge will reflect its unique and intricate mix of public and private institutions and processes. In a shift from an earlier era of scientific exploration financed primarily by government, the discoveries that paved the way for today’s biopharmaceuticals have been underwritten by private investors as well as public sources. . . . [Full Text of this Article]

                      What's this?